Oncology
Where the parent company has spent forty years. Solid tumors, hematologic malignancies, GI cancers.
Taiho Ventures
Taiho Pharmaceutical's venture arm. Early-stage oncology, immunology, urology.
AUM, April 2026
$400M
Under management
Mandate
Taiho Pharmaceutical is a Japanese specialty pharma company. Taiho Ventures is the venture arm. We invest in early-stage therapeutics — preclinical through proof of concept — and we usually show up on cap tables next to the institutional firm leading the round.
Therapeutic areas03 / 03
Allergy & Immunology
Taiho's second therapeutic franchise. Atopic disease, autoimmune indications, mast-cell biology.
Urology
And the third — adjacent to oncology, with its own clinical and commercial footprint in Japan.
$400MUnder management
27Portcos to date
2014Founded
3Therapeutic areas
How we co-invest
We co-invest. We don't lead.
We usually show up on the cap table next to the institutional firm leading the round. We bring strategic visibility into Taiho's commercial footprint in Japan and our R&D pipeline. We don't ask for veto rights, board seats, or the lead.
What we mean by strategic →